The anti-cancer properties of miR-340 plasmid-chitosan complexes (miR-340 CC) on murine model of breast cancer*

References

• Cuthrell KM, Tzenios N. Breast cancer: updated and deep insights. Int Res J Oncol. 2023;6(1):104–118.
   Google Scholar
• Dinakar YH, Kumar H, Mudavath SL, et al. Role of STAT3 in the initiation, progression, proliferation and metastasis of breast cancer and strategies to deliver JAK and STAT3 inhibitors. Life Sci. 2022;309:120996. doi: 10.1016/j.lfs.2022.120996.
   PubMed Web of Science ®Google Scholar
• Bekes I, Huober J. Extended adjuvant endocrine therapy in early breast cancer patients—review and perspectives. Cancers (Basel). 2023;15(16):4190. doi: 10.3390/cancers15164190.
   PubMed Web of Science ®Google Scholar
• Wu S, Lu J, Zhu H, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024;581:216508. doi: 10.1016/j.canlet.2023.216508.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yang L, Wu P, et al. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of Afadin. Mol Cancer. 2022;21(1):29. doi: 10.1186/s12943-022-01498-9.
   PubMed Web of Science ®Google Scholar
• Park M, Kim D, Ko S, et al. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci. 2022;23(12):6806. doi: 10.3390/ijms23126806.
   PubMed Web of Science ®Google Scholar
• Kerr AJ, Dodwell D, McGale P, et al. Adjuvant and neoadjuvant breast cancer treatments: a systematic review of their effects on mortality. Cancer Treat Rev. 2022;105:102375. doi: 10.1016/j.ctrv.2022.102375.
   PubMed Web of Science ®Google Scholar
• Katsura C, Ogunmwonyi I, Kankam HK, et al. Breast cancer: presentation, investigation and management. Br J Hosp Med. 2022;83(2):1–7. doi: 10.12968/hmed.2021.0459.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Y, Li D, et al. Mechanisms controlling microRNA expression in tumor. Cells. 2022;11(18):2852. doi: 10.3390/cells11182852.
   PubMed Web of Science ®Google Scholar
• Mitra R, Adams CM, Jiang W, et al. Pan-cancer analysis reveals cooperativity of both strands of microRNA that regulate tumorigenesis and patient survival. Nat Commun. 2020;11(1):968. doi: 10.1038/s41467-020-14713-2.
   PubMed Web of Science ®Google Scholar
• Budakoti M, Panwar AS, Molpa D, et al. Micro-RNA: the darkhorse of cancer. Cell Signal. 2021;83:109995. doi: 10.1016/j.cellsig.2021.109995.
   PubMed Web of Science ®Google Scholar
• Apollonova V, Plevako D, Garanin A, et al. Resistance of breast cancer cells to paclitaxel is associated with low expressions of miRNA-186 and miRNA-7. Cancer Drug Resist. 2023;6(3):596–610. doi: 10.20517/cdr.2023.19.
   PubMedGoogle Scholar
• Huang Z, Xu Y, Wan M, et al. miR-340: a multifunctional role in human malignant diseases. Int J Biol Sci. 2021;17(1):236–246. doi: 10.7150/ijbs.51123.
   PubMed Web of Science ®Google Scholar
• Lin N, Li W, Wang X, et al. Upregulation of miR-340 inhibits tumor growth and mesenchymal transition via targeting c-MET in glioblastoma. Cancer Manag Res. 2020;12:3343–3352. doi: 10.2147/CMAR.S250772.
   PubMed Web of Science ®Google Scholar
• Kashefi S, Mohammadi-Yeganeh S, Ghorbani-Bidkorpeh F, et al. Anti-cancer effects of a chitosan based nanoformulation expressing miR-340 on 4T1 breast cancer cells. J Pharm Sci. 2024;113(2):445–454. doi: 10.1016/j.xphs.2023.10.006.
   PubMed Web of Science ®Google Scholar
• Gupta A, Andresen JL, Manan RS, et al. Nucleic acid delivery for therapeutic applications. Adv Drug Deliv Rev. 2021;178:113834. doi: 10.1016/j.addr.2021.113834.
   PubMed Web of Science ®Google Scholar
• Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. Aaps J. 2021;23(4):78. doi: 10.1208/s12248-021-00608-7.
   PubMed Web of Science ®Google Scholar
• Chuan D, Jin T, Fan R, et al. Chitosan for gene delivery: methods for improvement and applications. Adv Coll Interface Sci. 2019;268:25–38. doi: 10.1016/j.cis.2019.03.007.
   PubMed Web of Science ®Google Scholar
• Sharma DK, Pattnaik G, Behera A. Recent developments in nanoparticles for the treatment of diabetes. J Drug Target. 2023;31(9):908–919. doi: 10.1080/1061186X.2023.2261077.
   PubMed Web of Science ®Google Scholar
• Nyamay’Antu A, Dumont M, Kedinger V, et al. Non-viral vector mediated gene delivery: the outsider to watch out for in gene therapy. Cell Gene Ther Insights. 2019;5(S1):51–57.
   Google Scholar
• Safarzadeh M, Mohammadi-Yeganeh S, Ghorbani-Bidkorbeh F, et al. Chitosan based nanoformulation expressing miR-155 as a promising adjuvant to enhance Th1-biased immune responses. Life Sci. 2022;297:120459. doi: 10.1016/j.lfs.2022.120459.
   PubMed Web of Science ®Google Scholar
• Adhikari HS, Yadav PN. Anticancer activity of chitosan, chitosan derivatives, and their mechanism of action. Int J Biomater. 2018;2018:2952085–2952029. doi: 10.1155/2018/2952085.
   PubMed Web of Science ®Google Scholar
• Salehi F, Behboudi H, Kavoosi G, et al. Chitosan promotes ROS-mediated apoptosis and S phase cell cycle arrest in triple-negative breast cancer cells: evidence for intercalative interaction with genomic DNA. RSC Adv. 2017;7(68):43141–43150. doi: 10.1039/C7RA06793C.
   Web of Science ®Google Scholar
• Metwaly AM, Abu-Saied MA, Gobaara IM, et al. Nicotinamide loaded chitosan nanocomplex shows improved anticancer potential: molecular docking, synthesis, characterization and in vitro evaluations. Curr Organ Chem. 2024;28(1):46–55. doi: 10.2174/0113852728283226231227061211.
   Web of Science ®Google Scholar
• Razavipour SF, Harikumar KB, Slingerland JM. p27 as a transcriptional regulator: new roles in development and cancer. Cancer Res. 2020;80(17):3451–3458. doi: 10.1158/0008-5472.CAN-19-3663.
   PubMed Web of Science ®Google Scholar
• Mohanty AK, Choudhary S, Kaushik JK, et al. Crystal structure of breast regression protein 39 (BRP39), a signaling glycoprotein expressed during mammary gland apoptosis, at 2.6 Å resolution. J Struct Biol. 2021;213(2):107737. doi: 10.1016/j.jsb.2021.107737.
   PubMed Web of Science ®Google Scholar
• Skytthe MK, Graversen JH, Moestrup SK. Targeting of CD163+ macrophages in inflammatory and malignant diseases. Int J Mol Sci. 2020;21(15):5497. doi: 10.3390/ijms21155497.
   PubMed Web of Science ®Google Scholar
• Huang C-Y, Ye Z-H, Huang M-Y, et al. Regulation of CD47 expression in cancer cells. Transl Oncol. 2020;13(12):100862. doi: 10.1016/j.tranon.2020.100862.
   PubMed Web of Science ®Google Scholar
• Piazzon MC, Lutfalla G, Forlenza M. IL10, a tale of an evolutionarily conserved cytokine across vertebrates. Crit Rev Immunol. 2016;36(2):99–129. doi: 10.1615/CritRevImmunol.2016017480.
   PubMed Web of Science ®Google Scholar
• Greiner JW, Morillon YM, Schlom J. NHS-IL12, a tumor-targeting immunocytokine. Immunotarget Ther. 2021;10:155–169. doi: 10.2147/ITT.S306150.
   PubMed Web of Science ®Google Scholar
• Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765. doi: 10.3389/fonc.2021.708765.
   PubMed Web of Science ®Google Scholar
• Yousuf T, Dar SB, Bangri SA, et al. Diagnostic implication of a circulating serum-based three-microRNA signature in hepatocellular carcinoma. Front Genet. 2022;13:929787. doi: 10.3389/fgene.2022.929787.
   PubMed Web of Science ®Google Scholar
• Kim ES, Choi YE, Hwang SJ, et al. IL-4, a direct target of miR-340/429, is involved in radiation-induced aggressive tumor behavior in human carcinoma cells. Oncotarget. 2016;7(52):86836–86856. doi: 10.18632/oncotarget.13561.
   PubMedGoogle Scholar
• Xiao C, Hong H, Yu H, et al. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway. Immunopharmacol Immunotoxicol. 2018;40(4):278–283. doi: 10.1080/08923973.2018.1455208.
   PubMed Web of Science ®Google Scholar
• Zhao P, Ma W, Hu Z, et al. Up-regulation of miR-340-5p promotes progression of thyroid cancer by inhibiting BMP4. J Endocrinol Invest. 2018;41(10):1165–1172. doi: 10.1007/s40618-018-0848-6.
   PubMed Web of Science ®Google Scholar
• Desai N, Rana D, Salave S, et al. Chitosan: a potential biopolymer in drug delivery and biomedical applications. Pharmaceutics. 2023;15(4):1313. doi: 10.3390/pharmaceutics15041313.
   PubMed Web of Science ®Google Scholar
• Gagliardi A, Giuliano E, Venkateswararao E, et al. Biodegradable polymeric nanoparticles for drug delivery to solid tumors. Front Pharmacol. 2021;12:601626. doi: 10.3389/fphar.2021.601626.
   PubMed Web of Science ®Google Scholar
• Bashir SM, Ahmed Rather G, Patrício A, et al. Chitosan nanoparticles: a versatile platform for biomedical applications. Materials. 2022;15(19):6521. doi: 10.3390/ma15196521.
   PubMed Web of Science ®Google Scholar
• Lima BV, Oliveira MJ, Barbosa MA, et al. Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of in vitro, in vivo and clinical studies. Biomater Sci. 2021;9(9):3209–3227. doi: 10.1039/d0bm01984d.
   PubMed Web of Science ®Google Scholar
• Vo JL, Yang L, Kurtz SL, et al. Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis. Oncoimmunology. 2014;3(12):e968001. doi: 10.4161/21624011.2014.968001.
   PubMed Web of Science ®Google Scholar
• Chu X-Y, Huang W, Wang Y-L, et al. Improving antitumor outcomes for palliative intratumoral injection therapy through lecithin–chitosan nanoparticles loading paclitaxel–cholesterol complex. Int J Nanomed. 2019;14:689–705. doi: 10.2147/IJN.S188667.
   PubMed Web of Science ®Google Scholar
• Boix-Montesinos P, Soriano-Teruel PM, Arminan A, et al. The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev. 2021;173:306–330. doi: 10.1016/j.addr.2021.03.018.
   PubMed Web of Science ®Google Scholar
• Fernandez S, Risolino M, Mandia N, et al. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 2015;34(25):3240–3250. doi: 10.1038/onc.2014.267.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Kurotaki D, Tsukamoto H, et al. Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer Sci. 2023;114(6):2220–2229. doi: 10.1111/cas.15751.
   PubMed Web of Science ®Google Scholar
• Erlandsson A, Carlsson J, Lundholm M, et al. M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate. 2019;79(4):363–369. doi: 10.1002/pros.23742.
   PubMed Web of Science ®Google Scholar
• Jamiyan T, Kuroda H, Yamaguchi R, et al. CD68-and CD163-positive tumor-associated macrophages in triple negative cancer of the breast. Virchows Arch. 2020;477(6):767–775. doi: 10.1007/s00428-020-02855-z.
   PubMed Web of Science ®Google Scholar
• Cohen N, Shani O, Raz Y, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of chitinase 3-like 1. Oncogene. 2017;36(31):4457–4468. doi: 10.1038/onc.2017.65.
   PubMed Web of Science ®Google Scholar
• Richer J, Spoelstra N, Williams M, et al. OR30-5 androgen-regulated secreted factors promote tumorigenesis and immune suppression in breast cancer. J Endocr Soc. 2022;6(Supplement_1):A883–A883. doi: 10.1210/jendso/bvac150.1828.
   Google Scholar
• Libreros S, Garcia-Areas R, Shibata Y, et al. Induction of proinflammatory mediators by CHI3L1 is reduced by chitin treatment: decreased tumor metastasis in a breast cancer model. Int J Cancer. 2012;131(2):377–386. doi: 10.1002/ijc.26379.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Carter C, Reid T, Brinkhaus F, Knox SJ, editors. Just eat it: a review of CD47 and SIRP-α antagonism. Semin Oncol. 2020;0093775447(2–3):117–124. doi: 10.1053/j.seminoncol.2020.05.009.
   Google Scholar
• Xi Q, Zhang J, Yang G, et al. Restoration of miR-340 controls pancreatic cancer cell CD47 expression to promote macrophage phagocytosis and enhance antitumor immunity. J Immunother Cancer. 2020;8(1):e000253. doi: 10.1136/jitc-2019-000253.
   PubMed Web of Science ®Google Scholar
• Huang X, Cao J, Zu X. Tumor-associated macrophages: an important player in breast cancer progression. Thorac Cancer. 2022;13(3):269–276. doi: 10.1111/1759-7714.14268.
   PubMed Web of Science ®Google Scholar
• Mirlekar B. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012. doi: 10.1177/20503121211069012.
   Web of Science ®Google Scholar
• Cirella A, Luri-Rey C, Di Trani CA, et al. Novel strategies exploiting interleukin-12 in cancer immunotherapy. Pharmacol Ther. 2022;239:108189. doi: 10.1016/j.pharmthera.2022.108189.
   PubMed Web of Science ®Google Scholar
• Mortezaee K, Majidpoor J. Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy. Cell Oncol. 2022;45(3):333–353. doi: 10.1007/s13402-022-00667-8.
   Web of Science ®Google Scholar
• Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78. doi: 10.1186/s12929-019-0568-z.
   PubMed Web of Science ®Google Scholar